Mechanism of action
Amino acids serve as the fundamental building blocks for protein synthesis and participate in numerous metabolic pathways. When administered parenterally, amino acids are directly absorbed into the systemic circulation and distributed to tissues throughout the body.
Protein synthesis: Amino acids are incorporated into polypeptide chains via ribosomal translation of mRNA, following activation by aminoacyl-tRNA synthetases. This process supplies structural proteins, enzymes, hormones, and immunoglobulins essential for cellular function and tissue repair.
Metabolic functions: Beyond protein synthesis, amino acids serve as precursors for neurotransmitters (tryptophan → serotonin, tyrosine → dopamine/norepinephrine), purine and pyrimidine bases, heme, creatine, and other bioactive molecules. Glucogenic amino acids can undergo deamination and enter gluconeogenesis during fasting states. Branched-chain amino acids (leucine, isoleucine, valine) are preferentially metabolized in skeletal muscle rather than liver, serving as both energy substrates and anabolic signals through mTOR pathway activation.
Essential vs nonessential: The nine essential amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine) cannot be synthesized de novo in humans and must be supplied exogenously. Conditionally essential amino acids (arginine, cysteine, glutamine, tyrosine) may require supplementation during critical illness, growth, or specific disease states when endogenous synthesis is insufficient.
- Nine essential amino acids cannot be synthesized: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine (PVT TIM HALL)
- Branched-chain amino acids (leucine, isoleucine, valine) are metabolized primarily in skeletal muscle, not liver, making them useful in hepatic encephalopathy
- Refeeding syndrome when starting nutrition in malnourished patients causes hypophosphatemia, hypokalemia, and hypomagnesemia due to intracellular shifts
- Phenylketonuria requires phenylalanine restriction and tyrosine supplementation; tyrosine becomes conditionally essential when phenylalanine hydroxylase is deficient
- Maple syrup urine disease results from branched-chain α-ketoacid dehydrogenase deficiency, causing BCAA accumulation and characteristic sweet-smelling urine
- Amino acids provide 4 kcal/g and are the nitrogen source in parenteral nutrition; nitrogen balance = (protein intake/6.25) − (urinary urea nitrogen + 4)
- Large neutral amino acids compete with levodopa for blood-brain barrier transport, potentially reducing levodopa efficacy in Parkinson patients
- Glutamine becomes conditionally essential during critical illness due to high consumption by immune cells and enterocytes
Indications
Amino acid solutions are indicated when enteral nutrition is impossible, insufficient, or contraindicated:
Parenteral nutrition: Amino acids constitute the nitrogen component of both total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN), providing 4 kcal/g. Standard formulations contain all essential amino acids plus nonessential forms in ratios designed to optimize nitrogen retention.
Protein-energy malnutrition: Severe malnutrition, cachexia, or prolonged catabolism from critical illness, burns, trauma, or major surgery may require protein supplementation beyond what can be achieved enterally.
Gastrointestinal dysfunction: Short bowel syndrome, intestinal obstruction, severe pancreatitis, inflammatory bowel disease flares, prolonged ileus, high-output enterocutaneous fistulas, and intractable vomiting or diarrhea may necessitate parenteral amino acid administration.
Metabolic stress states: Severe sepsis, multi-organ failure, extensive burns, and major trauma increase protein catabolism and nitrogen losses, often requiring augmented amino acid provision to prevent negative nitrogen balance.
Hepatic encephalopathy: Specialized branched-chain amino acid-enriched formulations may be used in hepatic failure, as BCAAs bypass hepatic metabolism and may reduce aromatic amino acid accumulation implicated in encephalopathy pathogenesis.
Renal failure: Modified amino acid formulations with predominantly essential amino acids and reduced nitrogen load are available for patients with renal insufficiency requiring parenteral nutrition.
Pharmacokinetics
Absorption and distribution: Parenterally administered amino acids bypass first-pass hepatic metabolism and enter systemic circulation directly. Distribution occurs rapidly to all tissues, with uptake mediated by amino acid transporters. Branched-chain amino acids preferentially distribute to skeletal muscle, while aromatic amino acids concentrate in the central nervous system.
Metabolism: Amino acid catabolism occurs primarily in the liver through transamination and oxidative deamination. The amino group is converted to ammonia, then to urea via the urea cycle for renal excretion. Carbon skeletons enter the citric acid cycle (glucogenic amino acids) or ketogenesis pathways (ketogenic amino acids). Branched-chain amino acids undergo initial transamination in muscle before their α-keto acids are oxidized.
Nitrogen balance: Net protein synthesis occurs when amino acid intake exceeds oxidative losses. Nitrogen balance = (protein intake/6.25) − (urinary urea nitrogen + 4 g for insensible losses). Positive nitrogen balance indicates anabolism; negative balance reflects net protein catabolism.
Renal excretion: Excess amino acids not utilized for protein synthesis undergo deamination, with nitrogen excreted as urea (80-90%), ammonia, creatinine, and other nitrogenous compounds. Small amounts of intact amino acids appear in urine, increasing with excessive intake or specific transport defects.
Adverse effects
Metabolic complications:
- Azotemia: Excessive amino acid administration or inadequate renal function causes elevated blood urea nitrogen as nitrogen load exceeds clearance capacity
- Hyperammonemia: Impaired urea cycle function (hepatic failure, urea cycle disorders) or overwhelming nitrogen load can cause ammonia accumulation, potentially precipitating encephalopathy
- Hyperglycemia: Amino acids stimulate insulin secretion; concurrent dextrose in parenteral nutrition increases this risk
- Electrolyte disturbances: Refeeding syndrome with hypophosphatemia, hypokalemia, and hypomagnesemia can occur when initiating nutrition in malnourished patients
Acid-base disorders: Amino acid metabolism generates acid equivalents; excessive administration may contribute to metabolic acidosis, particularly with formulations high in cationic amino acids. Conversely, metabolism of acetate salts often included as buffers produces bicarbonate.
Hepatobiliary complications: Prolonged parenteral nutrition with amino acids may contribute to parenteral nutrition-associated liver disease, characterized by cholestasis, steatosis, and elevated transaminases. Mechanisms include amino acid imbalances, lack of enteral stimulation, and bacterial translocation.
Hypersensitivity reactions: Rare allergic reactions to amino acid solutions or contaminants can occur, manifesting as rash, pruritus, bronchospasm, or anaphylaxis.
Catheter-related complications: Central venous access required for hypertonic amino acid solutions carries risks of infection, thrombosis, and mechanical complications (pneumothorax, vessel injury).
Osmotic effects: Hypertonic amino acid solutions administered peripherally may cause phlebitis and vein sclerosis. Rapid infusion of hyperosmolar solutions can cause osmotic diuresis and dehydration.
Contraindications and warnings
Absolute contraindications:
- Inborn errors of amino acid metabolism (phenylketonuria, maple syrup urine disease, homocystinuria) require specialized formulations lacking the problematic amino acid
- Severe uncorrected electrolyte or acid-base disturbances should be addressed before initiating amino acid infusion
- Hemodynamic instability or severe shock requires stabilization before parenteral nutrition initiation
Relative contraindications and cautions:
- Hepatic insufficiency: Use with caution; specialized branched-chain enriched formulations may be preferred to reduce aromatic amino acid load and encephalopathy risk
- Renal failure: Reduce dose or use essential amino acid formulations to minimize azotemia and uremic toxin accumulation
- Inborn errors of metabolism: Beyond classic aminoacidopathies, certain organic acidemias and urea cycle defects require protein restriction and specialized management
Pregnancy: Amino acids are Pregnancy Category C. While essential for fetal development, parenteral nutrition including amino acids should be used only when clearly needed, as safety data in pregnancy are limited.
Pediatric considerations: Premature infants and neonates have unique amino acid requirements, including higher needs for cysteine, taurine, and tyrosine, which are conditionally essential in this population. Specialized pediatric formulations address these needs.
Monitoring requirements: Regular assessment of nitrogen balance, electrolytes (particularly phosphate, potassium, magnesium), renal function (BUN, creatinine), hepatic function (transaminases, bilirubin, alkaline phosphatase), glucose, triglycerides, and acid-base status is essential during amino acid therapy. Serum amino acid levels may be monitored in specialized situations.
Drug interactions
Insulin and hypoglycemic agents: Amino acids stimulate insulin secretion and enhance insulin sensitivity. Concurrent administration with dextrose in parenteral nutrition significantly increases insulin requirements. Diabetic patients may require adjusted insulin dosing.
Levodopa: Large neutral amino acids (leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan) compete with levodopa for transport across the blood-brain barrier via the L-type amino acid transporter. High-protein meals or amino acid infusions may reduce levodopa efficacy in Parkinson disease patients.
Tetracycline antibiotics: Amino acids can chelate tetracyclines, potentially reducing antibiotic absorption if given enterally. This interaction is less relevant for parenteral amino acid administration.
Warfarin: Parenteral nutrition containing amino acids may alter vitamin K status and affect warfarin anticoagulation. Vitamin K in TPN formulations or changing nutrition status requires INR monitoring and dose adjustment.
Phenytoin: Amino acid infusions, particularly as components of parenteral nutrition, may decrease phenytoin levels through unclear mechanisms possibly involving altered protein binding or metabolism. Therapeutic drug monitoring is recommended.
Methionine and medications affecting homocysteine metabolism: High methionine intake can elevate homocysteine levels. Folate, vitamin B12, and vitamin B6 supplementation may be necessary to prevent hyperhomocysteinemia.
Calcineurin inhibitors (tacrolimus, cyclosporine): Parenteral nutrition including amino acids may alter drug levels through effects on hepatic metabolism and protein binding. Therapeutic drug monitoring is advised in transplant recipients.
Clinical pearls
Essential amino acid mnemonic: PVT TIM HALL — Phenylalanine, Valine, Threonine, Tryptophan, Isoleucine, Methionine, Histidine, Arginine (conditionally), Leucine, Lysine (arginine is essential in children).
Branched-chain amino acids (leucine, isoleucine, valine) are unique in being primarily metabolized in muscle rather than liver, making them important in hepatic encephalopathy management and muscle protein synthesis.
Maple syrup urine disease results from defective branched-chain α-ketoacid dehydrogenase, causing accumulation of leucine, isoleucine, and valine. The characteristic sweet-smelling urine gives the disease its name. Treatment requires dietary restriction of BCAAs.
Phenylketonuria results from phenylalanine hydroxylase deficiency, preventing conversion of phenylalanine to tyrosine. This makes tyrosine conditionally essential in PKU patients, who require phenylalanine-restricted diets supplemented with tyrosine.
Refeeding syndrome: When initiating nutrition in severely malnourished patients, intracellular shifts of phosphate, potassium, and magnesium driven by insulin and anabolism can cause life-threatening deficiencies. Start nutrition cautiously with electrolyte monitoring and repletion.
Glutamine: Though technically nonessential, glutamine becomes conditionally essential during critical illness due to high utilization by immune cells and enterocytes. Some specialized formulations include supplemental glutamine.
Nitrogen balance calculation: For every 6.25 g of protein, 1 g of nitrogen is contained. To calculate nitrogen intake from amino acids: (grams of amino acids/day) ÷ 6.25. Compare to nitrogen output (24-hour urinary urea nitrogen + 4 g insensible loss).
Standard vs specialized formulations: Standard amino acid solutions contain balanced mixtures; specialized formulations exist for hepatic failure (high BCAA, low aromatic amino acids), renal failure (essential amino acids only), and stress/trauma (enriched with branched-chain amino acids and glutamine).
PVT TIM HALL for the nine essential amino acids: Phenylalanine, Valine, Threonine, Tryptophan, Isoleucine, Methionine, Histidine, Arginine (conditionally essential in children), Leucine, Lysine
Practice questions
1. A 45-year-old man with alcoholic cirrhosis and hepatic encephalopathy is started on parenteral nutrition. His current ammonia level is elevated at 120 μmol/L (normal <50). Which amino acid formulation would be most appropriate for this patient?
2. A 3-day-old neonate presents with poor feeding, lethargy, and a distinctive sweet odor to the urine. Laboratory studies show elevated plasma levels of leucine, isoleucine, and valine with corresponding α-ketoacids. MRI shows cerebral edema. What is the appropriate nutritional management?
3. A 62-year-old woman with severe malnutrition (BMI 14 kg/m²) from prolonged illness is started on parenteral nutrition providing amino acids and dextrose. On day 3, she develops confusion, weakness, and arrhythmias. Labs show: phosphate 1.2 mg/dL (normal 2.5-4.5), potassium 2.8 mEq/L, magnesium 1.1 mg/dL. What is the most likely explanation?
Frequently asked questions
What are amino acids used for in clinical medicine?
Amino acids are used primarily as components of parenteral nutrition for patients who cannot meet protein requirements through enteral feeding. They provide the nitrogen source necessary for protein synthesis, wound healing, immune function, and metabolic processes. Clinical indications include severe malnutrition, prolonged bowel rest, short bowel syndrome, critical illness with high protein requirements, and gastrointestinal failure. Amino acid solutions are administered intravenously as part of total parenteral nutrition (TPN) or peripheral parenteral nutrition (PPN), typically combined with dextrose, lipids, electrolytes, and vitamins to provide complete nutrition.
What are the side effects of amino acid infusions?
The main adverse effects of amino acid infusions include azotemia (elevated blood urea nitrogen) from excessive nitrogen load, hyperammonemia particularly in patients with liver disease or urea cycle disorders, and electrolyte disturbances including refeeding syndrome with hypophosphatemia, hypokalemia, and hypomagnesemia in malnourished patients. Metabolic acidosis can occur with high doses. Hepatobiliary complications including cholestasis and elevated liver enzymes may develop with prolonged parenteral nutrition. Catheter-related infections and thrombosis are associated with the central venous access required for administration. Hyperglycemia may occur due to insulin stimulation, especially when amino acids are combined with dextrose.
What is the difference between essential and nonessential amino acids?
Essential amino acids cannot be synthesized by the human body and must be obtained from dietary sources or parenteral administration. The nine essential amino acids are histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Nonessential amino acids can be synthesized endogenously from other precursors and do not require dietary intake under normal conditions. However, some nonessential amino acids become conditionally essential during certain states: arginine in children and critical illness, cysteine in premature infants, glutamine during stress, and tyrosine in phenylketonuria patients who cannot convert phenylalanine to tyrosine.
How do amino acids affect patients with liver disease?
In liver disease, amino acid metabolism is impaired, leading to characteristic plasma amino acid imbalances with elevated aromatic amino acids (phenylalanine, tyrosine, tryptophan) and decreased branched-chain amino acids (leucine, isoleucine, valine). This imbalance may contribute to hepatic encephalopathy, as aromatic amino acids cross the blood-brain barrier and generate false neurotransmitters. Standard amino acid infusions can worsen azotemia and hyperammonemia due to impaired urea cycle function. Specialized branched-chain amino acid-enriched formulations are available for hepatic failure patients, designed to normalize plasma amino acid ratios and potentially reduce encephalopathy risk while providing necessary protein for healing and immune function.
What is refeeding syndrome and how is it related to amino acids?
Refeeding syndrome is a potentially fatal complication that occurs when nutrition, including amino acids, is initiated in severely malnourished patients. During starvation, the body adapts to using fat and protein as energy sources with low insulin levels. When feeding resumes, insulin secretion increases dramatically, driving glucose, phosphate, potassium, and magnesium into cells for anabolic processes including protein synthesis from administered amino acids. This causes life-threatening serum electrolyte deficiencies: hypophosphatemia, hypokalemia, and hypomagnesemia. Prevention requires starting nutrition slowly with close electrolyte monitoring and aggressive repletion. Thiamine should be given before refeeding to prevent Wernicke encephalopathy, another complication of refeeding.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: B05BA01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.